Biocause Pharma(SZ:000627) Guo Ji Jin Rong Bao·2025-09-26 11:05Core Viewpoint - The company *ST Tianmao has received a decision from the Shenzhen Stock Exchange to terminate its stock listing due to continuous financial losses and failure to meet reporting obligations [1][5]. Group 1: Company Overview - *ST Tianmao was established in November 1993 and listed on the Shenzhen Stock Exchange in November 1996, primarily engaged in various personal insurance businesses including life, health, and accident insurance [4]. Group 2: Delisting Process - The company announced its intention to voluntarily delist on August 8, 2023, submitted the delisting application on September 4, and the Shenzhen Stock Exchange accepted the application on September 10, with the final decision made on September 25, 2023, completing the delisting process in approximately two months [3][5]. Group 3: Financial Performance - The company's net profit attributable to shareholders has declined for four consecutive years, with significant losses in the last two years. The net profit figures from 2020 to 2023 show a decline of 67.32%, 18.88%, 41.78%, and 337.82%, respectively. In 2023, the company reported a net loss of 650 million yuan, and for the first three quarters of 2024, the loss was 333 million yuan [5]. - The company projected a net loss of 500 million to 750 million yuan for 2024, with a non-recurring net profit loss forecasted between 503 million and 753 million yuan [5]. Group 4: Regulatory Compliance and Risks - Prior to the voluntary delisting, the company had issued multiple risk warning announcements regarding the potential for termination of its listing due to its inability to disclose the 2024 annual report and the 2025 Q1 report within the statutory timeframe [6]. - Since 2025, a total of 25 listed companies, including B-share companies, have completed the delisting process, with nine companies facing financial delisting, indicating a broader trend in the market [6].